logo
  

Astec Industries Q4 Adj. EPS Tops Estimates, But Net Sales Miss

Astec Industries, Inc. (ASTE) on Wednesday reported a net income for the fourth quarter of $14.9 million or $0.65 per share, compared to a net loss of $1.0 million or $0.04 per share in the prior-year quarter.

Excluding items, adjusted net income for the quarter were $0.90 per share, compared to $0.34 per share in the year-ago quarter.

Net sales for the quarter grew 3.6 percent to $337.2 million from $249.9 million in the same quarter last year.

On average, four analysts polled by Thomson Reuters expected the company to report earnings of $0.66 per share on revenues of $347.29 million for the quarter. Analysts' estimates typically exclude special items.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
With traders reacting positively to closely watched consumer price inflation data, stocks moved sharply higher during trading on Wednesday. The major averages added to Tuesday's gains, setting new record closing highs. The rally on Wall Street came following the release of a Labor Department report showing consumer prices in the U.S. rose by slightly less than expected in the month of April. The Commerce Department released a report on Wednesday showing a modest decrease in business inventories in the U.S. in the month of March. The report said business inventories edged by 0.1 percent in March after climbing by 0.3 percent in February. The dip matched economist estimates. With higher mortgage rates weighing on sentiment, the National Association of Home Builders released a report on Wednesday showing an unexpected deterioration in U.S. homebuilder confidence in the month of May. The report said the NAHB/Wells Fargo Housing Market Index tumbled to 45 in May from 51 in April. Economists had expected the index to come in unchanged.

This week, we bring a mix of medical breakthroughs and setbacks. Lyko's MDMA therapy could become the first FDA-approved psychedelic treatment if all goes well as planned. A tragic loss occurred in Pfizer's Duchenne trial and a new study has raised concerns about ultra-processed foods. Find out why Long Beach declared a public health emergency and how Novavax's actions signal optimism.

View More Videos
Follow RTT